Prospective Observational Registry of EUS-Guided Radiofrequency and Microwave Ablation for Pancreatic and Gastrointestinal Lesions

What this Trial Is About

Researchers are observing adult patients aged 18 and over who receive endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) or microwave ablation (MWA) for pancreatic, gastrointestinal, or hepatobiliary lesions as part of their usual medical care. This registry collects detailed clinical data over time without changing standard treatment. The main goals include tracking changes in lesion size through routine imaging and monitoring overall survival after ablation, along with secondary measures like tumor markers, side effects, non-target lesion changes, and patient symptoms. This observational registry collects data from patients undergoing RFA or MWA targeted at clinically identified lesions. The registry does not assign treatments but records information from routine clinical procedures performed as standard care. Data includes measurements of tumor markers and quality of life scores at specific intervals after ablation, up to 12 months and beyond. Participants contribute data through their medical records and routine clinical visits. Researchers assess lesion size changes at 1, 3, 6, and 12 months post-ablation and monitor survival up to three years. They also track adverse events related to the procedure and patient-reported quality of life using validated questionnaires. The total study duration extends through regular clinical follow-up, ensuring comprehensive long-term monitoring.

EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions Registry